Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Grows By 2,767.7%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 493,245 shares, an increase of 2,767.7% from the May 31st total of 17,200 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 5,161,875 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics has an average rating of “Sell”.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ:INDP opened at $3.26 on Friday. The stock has a market capitalization of $369.16 million, a price-to-earnings ratio of -0.21 and a beta of 1.25. Indaptus Therapeutics has a 1-year low of $0.92 and a 1-year high of $13.44. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.34.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.87) by $1.64.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.